Pemetrexed in advanced non-small-cell lung cancer

@article{Fuld2010PemetrexedIA,
  title={Pemetrexed in advanced non-small-cell lung cancer},
  author={A. Fuld and K. Dragnev and J. Rigas},
  journal={Expert Opinion on Pharmacotherapy},
  year={2010},
  volume={11},
  pages={1387 - 1402}
}
  • A. Fuld, K. Dragnev, J. Rigas
  • Published 2010
  • Medicine
  • Expert Opinion on Pharmacotherapy
  • Importance of the field: Current therapeutic options for advanced non-small-cell lung cancer (NSCLC) yield relatively modest improvements in survival leading to an ongoing search for new active treatment agents. In the past decade, pemetrexed has had an increasingly established role in the treatment of advanced NSCLC in both first- and second-line settings. Areas covered in this review: Currently available published data on mechanism of action, pharmacokinetics, safety and efficacy of… CONTINUE READING
    30 Citations
    Pemetrexed disodium in ovarian cancer treatment
    • 8
    • Highly Influenced
    Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.
    • M. Ranson, M. Reck, +7 authors C. Twelves
    • Medicine
    • Annals of oncology : official journal of the European Society for Medical Oncology
    • 2010
    • 39
    Pharmacokinetic evaluation of pemetrexed
    • 14
    A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutation: Final Overall Survival and Biomarker Analysis.
    • 3

    References

    SHOWING 1-10 OF 106 REFERENCES
    First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype
    • 23
    Histologic subtype in NSCLC: does it matter?
    • 64
    • PDF
    Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced-Stage Non-Small Cell Lung Cancer
    • 46
    • Highly Influential
    • PDF
    The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
    • 631
    • Highly Influential
    • PDF
    Efficacy Differences of Pemetrexed by Histology in Pretreated Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Review of Results from an Open-Label Randomized Phase II Study
    • K. Kubota, S. Niho, +4 authors M. Fukuoka
    • Medicine
    • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
    • 2009
    • 31
    Duration of chemotherapy for metastatic non-small-cell lung cancer: more may be better after all.
    • J. Schiller, S. Ramalingam
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2009
    • 14
    Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.
    • A. Adjei, S. Mandrekar, +8 authors R. Zinner
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2010
    • 82